CNTA
Centessa Pharmaceuticals plc
$39.59
-0.05%
2026-05-08
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Key Fundamentals
Forward P/E
-20.88
EPS (TTM)
$-1.78
ROE
-57.4%
Profit Margin
0.0%
Debt/Equity
24.17
Price/Book
12.57
Beta
1.57
Market Cap
$6.13B
Avg Volume (10D)
1.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$40.25
60D Low
$23.03
Avg Volume
2.6M
Latest Close
$39.59
Get breakout alerts for CNTA
Sign up for Breakout Scanner to receive daily notifications when CNTA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Centessa Pharmaceuticals plc (CNTA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CNTA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CNTA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.